Overview

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts. The investigators will use blood stem cells collected from bone marrow to help subjects recover their blood counts, a procedure called autologous stem cell transplant or stem cell rescue. This way, the investigators expect to be able to safely deliver very high doses of temozolomide. This study is only available at Tufts Medical Center.
Phase:
Phase 1
Details
Lead Sponsor:
Tufts Medical Center
Treatments:
Dacarbazine
Temozolomide